Targeted Sequencing Panel covering 19 genes involved in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).

Targeted Sequencing Panel covering 50 genes involved in cancer. This panel is ideal for ovarian cancer, breast cancer, prostate cancer and bladder cancer, providing analysis of genes that may offer suitable drug targets.

Targeted Sequencing Panel covering 22 genes involved in lung cancer, bowel cancer, melanoma and pancreatic cancer. For lung cancer, we are also able to test for RNA fusions including ALK, RET, ROS-1 and NTRK-1.

Genetic Testing is now available for ctDNA in blood. DNA is extracted from plasma and highly sensitive testing is then used to detect specific DNA mutations in the circulating cell-free tumour DNA enabling early detection of cancer, monitoring of disease progression and response to treatment.

Several other molecular pathology tests are under development. For information about specific requirements please contact the laboratory. Medicare rebates may be available on some tests.